Creating a new treatment to prevent lung cancer using immune system activation
Developing a novel agonist of CD137 for cancer immunoprevention
['FUNDING_OTHER'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-10877474
This study is testing a new treatment that helps boost the immune system to prevent lung cancer in people who are at higher risk because of their environment, using a special agent that could work for many types of tumors.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-10877474 on ClinicalTrials.gov |
What this research studies
This research investigates a novel treatment that activates the immune system to prevent lung cancer, particularly in individuals at high risk due to environmental factors. The approach focuses on a specific pathway in the immune system known as the 4-1BB costimulatory pathway, which enhances the activity of CD8+ T cells, crucial for fighting cancer. By using a new agent called SA-4-1BBL, the research aims to develop a method that does not rely on identifying specific cancer antigens, making it potentially applicable to a broader range of tumors. The study will be conducted in preclinical models that mimic high-risk populations, providing insights into its effectiveness before moving to human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for lung cancer due to environmental exposures.
Not a fit: Patients who do not have a high risk of lung cancer or those with existing cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking method for preventing lung cancer in high-risk individuals.
How similar studies have performed: Previous research has shown promise in using immune system activation for cancer treatment, but this specific approach is novel and untested in the context of lung cancer prevention.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHIRWAN, HAVAL — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: SHIRWAN, HAVAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.